CHF10.90
0.37% today
SIX Swiss Exchange, Aug 12, 05:31 pm CET
ISIN
CH1129677105
Symbol
MEDX

Medmix Target price 2025 - Analyst rating & recommendation

Medmix Classifications & Recommendation:

Buy
88%
Hold
13%

Medmix Price Target

Target Price CHF19.38
Price CHF10.90
Potential
Number of Estimates 4
4 Analysts have issued a price target Medmix 2026 . The average Medmix target price is CHF19.38. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend Medmix to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Medmix stock has an average upside potential 2026 of . Most analysts recommend the Medmix stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million CHF 483.90 490.22
0.55% 1.31%
EBITDA Margin 16.62% 17.64%
10.15% 6.17%

4 Analysts have issued a sales forecast Medmix 2025 . The average Medmix sales estimate is

CHF490m
Unlock
. This is
4.73% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF513m 9.64%
Unlock
, the lowest is
CHF463m 1.09%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF484m 0.55%
2025
CHF490m 1.31%
Unlock
2026
CHF513m 4.58%
Unlock
2027
CHF540m 5.33%
Unlock
2028
CHF504m 6.68%
Unlock
2029
CHF525m 4.19%
Unlock
2030
CHF549m 4.50%
Unlock
2031
CHF573m 4.51%
Unlock
2032
CHF602m 5.00%
Unlock

4 Analysts have issued an Medmix EBITDA forecast 2025. The average Medmix EBITDA estimate is

CHF86.5m
Unlock
. This is
7.71% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF89.9m 11.93%
Unlock
, the lowest is
CHF82.3m 2.51%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF80.4m 9.54%
2025
CHF86.5m 7.58%
Unlock
2026
CHF95.5m 10.43%
Unlock
2027
CHF107m 12.27%
Unlock

EBITDA Margin

2024 16.62% 10.15%
2025
17.64% 6.17%
Unlock
2026
18.63% 5.61%
Unlock
2027
19.86% 6.60%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share CHF -0.18 0.34
1,900.00% 288.89%
P/E 32.26
EV/Sales 1.35

4 Analysts have issued a Medmix forecast for earnings per share. The average Medmix EPS is

CHF0.34
Unlock
. This is
361.54% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF0.40 407.69%
Unlock
, the lowest is
CHF0.27 307.69%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF-0.18 1,900.00%
2025
CHF0.34 288.89%
Unlock
2026
CHF0.47 38.24%
Unlock
2027
CHF0.65 38.30%
Unlock

P/E ratio

Current -84.15 61.04%
2025
32.26 138.33%
Unlock
2026
23.12 28.33%
Unlock
2027
16.94 26.73%
Unlock

Based on analysts' sales estimates for 2025, the Medmix stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.42 2.16%
2025
1.35 4.59%
Unlock
2026
1.30 4.38%
Unlock
2027
1.23 5.06%
Unlock
2028
1.32 7.15%
Unlock
2029
1.27 4.01%
Unlock
2030
1.21 4.32%
Unlock
2031
1.16 4.31%
Unlock
2032
1.10 4.77%
Unlock

P/S ratio

Current 0.98 5.51%
2025
0.94 4.51%
Unlock
2026
0.90 4.38%
Unlock
2027
0.85 5.05%
Unlock
2028
0.91 7.15%
Unlock
2029
0.87 4.02%
Unlock
2030
0.84 4.31%
Unlock
2031
0.80 4.30%
Unlock
2032
0.76 4.77%
Unlock

Current Medmix Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
RESEARCH PARTNERS AG
Locked
Locked
Locked Feb 26 2025
Analyst Rating Date
Locked
RESEARCH PARTNERS AG:
Locked
Locked
Feb 26 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today